(Q37218304)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

title

Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale" (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

Corrigendum: Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale"

23 March 2020

corrigendum / erratum

0 references

author

Sabrina Rossetti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Carla Cavaliere

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Chiara Della Pepa

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Anna Crispo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Gelsomina Iovane

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Gennaro Ciliberto

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Gaetano Facchini

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

author name string

Sabrina C Cecere

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Marilena Di Napoli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Raffaele Piscitelli

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Domenico Sorrentino

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Piera Maiolino

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Paolo Muto

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Sisto Perdonà

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Massimiliano Berretta

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Sandro Pignata

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Carmine D'Aniello

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

publication date

31 August 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

Frontiers in Pharmacology

23 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

page(s)

287

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting

23 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Molecular genetics of clear-cell renal cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Contemporary management of renal cell carcinoma (RCC) in Victoria: implications for longer term outcomes and costs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Combination therapy in metastatic renal cell cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

New treatment approaches in renal cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Systemic therapy for renal cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Pazopanib versus sunitinib in renal cancer

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5005368

3 September 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/27630568

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27630568

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3389/FPHAR.2016.00287

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27630568%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

1 reference